Spinal Cord Injury Induced Osteoporosis: Case Report and Current Literature

Abdulai Bangura,1 Thomas Shuler,2 Lisa Wright,1 Anne Lake.3

Abstract
Background: Among the various etiologies of osteoporosis, spinal cord injury has a drastic progression of the disease, causing weekly bone loss. This is due to a multifactorial and unfavorable set of consequences involving bone metabolism.1 Following bone peak mass at 30 years of age, men and women lose bone mineral density (BMD) at a rate of 0.3% and 0.5% per year, respectively. Post-menopausal women lose BMD at a rate of 2% per year.2 However, individuals with SCI lose 1% of BMD per week.3

Due to the significant amount of bone loss leading to osteoporotic fractures, individuals with SCI are at an increased risk for comorbidities including osteomyelitis, skin pressure ulcers from bracing and bedrest, and hypertensive crisis from autonomic dysreflexia.4,5 The National Spinal Cord Injury Statistical Center (NSCISC) reports an incidence of 17,810 new SCI cases in the United States each year with a current prevalence that could reach 368,000 people. According to the NSCISC data sheets, both the incidence and prevalence have increased over the last couple years with the most common cause being motor vehicle accidents. Additional common causes are acts of violence (primarily gunshot wounds) and sports/recreational injuries.6 At this time, there is no definitive treatment for the prevention of osteoporosis in these individuals. We hope to establish the current pathophysiology to provide a basis for future innovative therapies.

People with SCI are immediately challenged by the consequences of mechanical unloading, neural denervation with subsequent vascular dysregulation, and biomarker abnormalities. All of which contribute to either increased bone resorption, decreased bone formation, or a combination of both. Mechanical unloading is noteworthy as it leads to a cascade of events that is expected to have the strongest association with bone loss.7

In both human and animal studies, a decrease of mechanical loading on bone has been found to have a significant association with an increase in sclerostin protein synthesis and vice-versa.8,9 Sclerostin is encoded by the sclerostin gene (SOST) and it is expressed by many tissues, but primarily by osteocytes. Most recent literature has recognized sclerostin as the principal mediator of SCI osteoporosis.9 Sclerostin inhibits the Wnt/b-catenin pathway, which is a vital component of bone formation. Furthermore, sclerostin increases the expression of receptor activator of nuclear factor kappa-B ligand (RANKL) and decreases the expression of receptor activity of osteoprotegerin (OPG) which ultimately increases bone resorption.10

Due to sclerostin’s strong correlation with mechanical unloading, it is a great contributor to SCI osteoporosis. Sclerostin demonstrates an inverse relationship with BMD within the first 5 years following SCI, with sclerostin levels increasing as BMD decreases. After 5 years, the relationship reverses into a positive relationship with sclerostin levels.

Highlights:
- The most recent findings on the pathophysiology, treatment, and management of spinal cord injury induced osteoporosis.
- A basis for the derivation of future innovative therapies for spinal cord injury induced osteoporosis.
- Favorable treatments and management for best prognosis in spinal cord injury induced osteoporosis.

The Case: We have a 57-year-old man with a history of AIS grade A spinal cord injury, level T11 with rod fixation from a motorcycle collision at age 21. His fracture history following the injury includes tibia, femur, and vertebral fractures. Bone mineral density imaging revealed notable T-scores ranging from -3.1 to -3.4 at the hip and femurs. Treatment plan consisted of teriparatide, dietary supplements, and physical therapy. Biomarkers from baseline to post one month of treatment revealed the following: procollagen type 1 N-terminal propeptide from 38 mcg/L to 70 mcg/L and C-terminal telopeptide from 209 pg/mL to 88 pg/mL, representing an increased bone formation and decreased bone resorption, respectively. After two years, bone mineral density T-scores improved to -2.7 on the left and the patient was capable of standing for the first time with the assistance of a standing frame.

Conclusion: Our case exemplified the progression of the disease and treatment options. A basis for the derivation of future innovative therapies has been covered. Favorable treatments and management are described in the review.

Key Words: Spinal Cord Injuries; Osteoporosis; Teriparatide; Bone Density; SOST protein; human (Source: MeSH-NLM).

Introduction
Among the various etiologies of osteoporosis, spinal cord injury (SCI) has a drastic progression of the disease, causing weekly bone loss. This is due to a multifactorial and unfavorable set of consequences involving bone metabolism. Following bone peak mass at 30 years of age, men and women lose bone mineral density (BMD) at a rate of 0.3% and 0.5% per year, respectively. Post-menopausal women lose BMD at a rate of 2% per year. However, individuals with SCI lose 1% of BMD per week. Due to the significant amount of bone loss leading to osteoporotic fractures, individuals with SCI are at an increased risk for comorbidities including osteomyelitis, skin pressure ulcers from bracing and bedrest, and hypertensive crisis from autonomic dysreflexia. The National Spinal Cord Injury Statistical Center (NSCISC) reports an incidence of 17,810 new SCI cases in the United States each year with a current prevalence that could reach 368,000 people. According to the NSCISC data sheets, both the incidence and prevalence have increased over the last couple years with the most common cause being motor vehicle accidents. Additional common causes are acts of violence (primarily gunshot wounds) and sports/recreational injuries. At this time, there is no definitive treatment for the prevention of osteoporosis in these individuals. We hope to establish the current pathophysiology to provide a basis for future innovative therapies.

People with SCI are immediately challenged by the consequences of mechanical unloading, neural denervation with subsequent vascular dysregulation, and biomarker abnormalities. All of which contribute to either increased bone resorption, decreased bone formation, or a combination of both. Mechanical unloading is noteworthy as it leads to a cascade of events that is expected to have the strongest association with bone loss.

In both human and animal studies, a decrease of mechanical loading on bone has been found to have a significant association with an increase in sclerostin protein synthesis and vice-versa. Sclerostin is encoded by the sclerostin gene (SOST) and it is expressed by many tissues, but primarily by osteocytes. Most recent literature has recognized sclerostin as the principal mediator of SCI osteoporosis. Sclerostin inhibits the Wnt/b-catenin pathway, which is a vital component of bone formation. Furthermore, sclerostin increases the expression of receptor activator of nuclear factor kappa-B ligand (RANKL) and decreases the expression of receptor activity of osteoprotegerin (OPG) which ultimately increases bone resorption.

Due to sclerostin’s strong correlation with mechanical unloading, it is a great contributor to SCI osteoporosis. Sclerostin demonstrates an inverse relationship with BMD within the first 5 years following SCI, with sclerostin levels increasing as BMD decreases. After 5 years, the relationship reverses into a positive relationship with sclerostin levels.

1 MS. Trinity School of Medicine, Department of Research, Ratho Mill, St. Vincent and the Grenadines, United States.
2 MD. Carilion Clinic, Department of Orthopaedics, Roanoke, Virginia, United States.
3 MD. Trinity School of Medicine, Department of Research, Ratho Mill, St. Vincent and the Grenadines, United States.
4 DNP. Wake Forest Baptist Health, Department of Orthopaedics, Winston-Salem, North Carolina, United States.

About the Author: Abdulai Bangura is currently a third-year medical student of Trinity School of Medicine, Ratho Mill, St. Vincent and the Grenadines of a 4-year program. He is also one of the five fellows selected for the R Adams Cowley Shock Trauma Center Orthopaedic Traumatology Research Fellowship for the 2020-2021 year.

Correspondence:
Abdulai Bangura
Address: Trinity School of Medicine, Department of Research, Ratho Mill, St. Vincent and the Grenadines 925 Woodstock Road, Suite 200, United States.
Email: abdulai.bangura.21@trinity.edu

Editor: Francisco J. Bonilla-Escobar
Student Editors: David Ben-Nun, Thanthima Suwanthawornkul, Nikoleta Tellios
Copyeditor: Leah Komer
Proofreader: Nikoleta Tellios
Layout Editor: Fatma Monib

DOI: 10.5195/ijms.2021.535
Publication: Jun 30, 2021
Process: Peer-reviewed
now decreasing as BMD levels continue to decrease.\textsuperscript{11} One study sampled men with chronic SCI (2+ years post injury) and as the number of years following the SCI increased, the levels of sclerostin and BMD decreased together. It is important to note that the duration of injury for the subjects ranged from 4.1 to 42.0 years. Their findings suggested that circulating sclerostin levels in chronic SCI is a potential indicator of osteoporosis severity.\textsuperscript{4}

Although mechanical unloading appears to be the point of attention, other factors impact SCI osteoporosis. As expected, there would be neural damage which reduces bone function. Sympathetic stimulation contributes to bone maintenance and it has been found that sympathetic denervation of bone in animal models revealed increased bone resorption, and decreased bone mineralization. Furthermore, sympathetic denervation causes subsequent vascular dysregulation. The impairment of vascular regulation allows increased capillary and venous blood pooling which leads to increased intraluminal pressure. A potential consequence of local blood pooling is osteoclast formation.\textsuperscript{4} For these reasons, sympathetic denervation and subsequent vascular dysregulation are potential contributors to osteoporosis in individuals with SCI.

In addition to mechanical unloading and sympathetic denervation, biomarkers including vitamin D, parathyroid hormone (PTH), and fat, contribute to osteoporosis in individuals with SCI. Although the prevalence of vitamin D deficiency is high among the general population, people with SCI are still at an increased risk for vitamin D insufficiency or deficiency.\textsuperscript{13} In regards to PTH, the high activity of bone resorption following SCI induces hypercalcemia leading to the suppression of PTH synthesis.\textsuperscript{14} PTH has been found to suppress sclerostin levels in human and animal studies.\textsuperscript{15,16} Therefore, a decrease in PTH can subsequently lead to further bone loss by increasing sclerostin levels. Fat has also been found to affect bone maintenance in SCI individuals. Multiple studies have revealed that people with SCI have a greater percentage of body fat in comparison with matched age and sex controls, demonstrating a greater risk of obesity in people with SCI than in the general population.\textsuperscript{3}

It is established that fat has an osteoprotective effect on bone by way of increased mechanical loading which induces bone formation.\textsuperscript{17} However, with SCI, muscle paralysis prevents mechanical loading and may disrupt this process. In addition, fat releases leptin which mainly regulates appetite and energy expenditure in the hypothalamus.\textsuperscript{18} Leptin also has additional properties including bone formation regulation. Leptin can provide sympathetic inhibition to osteoblasts and suppress bone formation by way of beta-2-adrenergic receptors on the osteoblast cell surface.\textsuperscript{4} Leptin levels have been shown to be elevated in individuals with SCI in comparison with the general population.\textsuperscript{19} Adiponectin is a hormone that is produced by adipocytes or fat cells. In both human and animal studies, increased levels of adiponectin have been associated with increased bone loss.\textsuperscript{1} One study revealed that adiponectin has an inverse relationship with BMD in individuals with chronic SCI. The same study revealed that when these individuals participated in walking activities, the inverse relationship was no longer found.\textsuperscript{20} However, research of the relationship between adiponectin and bone loss specifically in the SCI population is currently ongoing.

The Case

History

A 57-year-old man with a history of level T11, AIS grade A SCI with rod fixation from a motorcycle accident at age 21 was referred to our fracture liaison and bone health clinic for a bone health evaluation. The patient himself provided consent for his information to be included in publications. He is 5’10” with a body mass index (BMI) of 23.8. He has a 7.5 pack-years smoking history with cessation of smoking in 2015. His fracture history following the SCI included right tibia fracture, right femur fracture, and left femur fracture all of which were associated with the mechanical attempts of standing and therapy. There is no record of his treatment plan or laboratory results prior to his first visit at our bone health clinic.

Investigation

Physical examination was consistent with a T11 level paraplegia with anesthesia at the T12 dermatome and motor examination with flaccid lower extremity paralysis, and 2+ distal pulses. The left lower extremity had a slight knee contracture of 5 to 10 degrees. Bone density imaging referenced severe osteoporosis in the total hip and femoral neck bilaterally (Table 1). BMD imaging revealed the following notable T-scores: right hip and right femoral neck [T-score -3.1], left hip and left femoral neck [T-score -3.4]. However, it is important to note that optimal leg positioning for BMD imaging was not achieved due to the patient’s limitations. Furthermore, radiological imaging represented diffuse bony demineralization of the left femur (Figure 1). Laboratory orders were ascertained for a baseline which included bone biomarkers for comparing with post treatment evaluations (Table 2).

Table 1. Bone density imaging referenced severe osteoporosis in the total hip and femoral neck bilaterally.

| Component                              | Value | Comment                              |
|----------------------------------------|-------|--------------------------------------|
| BMD Spine (L1-L4)                      | 1.282 | Could only scan L1-L4 due to hardware in L1-L2 |
| T-Score Spine (L1-L4)                  | 0.4   |                                      |
| Z-Score Spine (L1-L4)                  | 0.7   |                                      |
| BMD Right Hip                          | 0.671 |                                      |
| T-Score Right Hip                      | -3.1  | Osteoporosis                          |
| Z-Score Right Hip                      | -2.2  |                                      |
| BMD Left Hip                           | 0.622 |                                      |
| T-Score Left Hip                       | -3.4  | Osteoporosis                          |
| Z-Score Left Hip                       | -2.6  |                                      |
| BMD Mean Hip                           | 0.674 | Unable to position legs optimally for scanning |
| T-Score Mean Hip                       | -3.3  | osteoporosis                          |
| Z-Score Mean Hip                       | -2.4  |                                      |
| BMD Right Femoral Neck                 | 0.671 |                                      |
| T-Score Right Femoral Neck             | -3.1  | osteoporosis                          |
| Z-Score Right Femoral Neck             | -2.2  |                                      |
| BMD Left Femoral Neck                  | 0.622 |                                      |
| T-Score Left Femoral Neck              | -3.4  | osteoporosis                          |
| Z-Score Left Femoral Neck              | -2.6  |                                      |

Table 2. Baseline and post-therapy biomarkers.

| Lab               | Reference range | Baseline | 1 month |
|-------------------|-----------------|----------|---------|
| P1NP              | 30-110 mcg/L    | 38 mcg/L | 70 mcg/L|
| Vitamin D         | 30-100 mg/dL    | 26 mg/dL | 50 mg/dL|
| Alk Phos Bone     | 7.6-14.9 mcg/L  | 12.1 mcg/L | 14.9 mcg/L |
| CTX               | 87-345 pg/mL    | 209 pg/mL | 88 pg/mL |
| PTH               | 18.4-88.0 pg/mL | 52.8 pg/mL | 72.4 pg/mL |
| Phosphorous       | 2.5-4.6 mg/dL   | 3.3 mg/dL | 4.2 mg/dL |
| Calcium           | 8.5-10.7 mg/dL  | 9.8 mg/dL | 10.4 mg/dL |
| Creatinine        | 0.5-1.4 mg/dL   | 0.46 mg/dL | 0.58 mg/dL |
| Ionized Calcium   | 1.13-1.32 mmol/L| 1.19 mmol/L | 1.21 mmol/L |

Management

We considered the patient’s past history, imaging, and laboratory results to align the following treatment plan: teriparatide [rDNAorigin] injection once daily, vitamin D2 (50,000 iu’s) once weekly for 8 weeks, vitamin D3 (2000 iu’s) once daily, vitamin K2, and calcium citrate 600 mg once daily. Additional supplements included magnesium citrate and creatine. Treatment medication was chosen based upon the goal of promoting bone formation and synergistically aligning the patient to a

| Lab               | Reference range | Baseline | 1 month |
|-------------------|-----------------|----------|---------|
| Ionized Calcium   | 1.13-1.32 mmol/L| 1.19 mmol/L | 1.21 mmol/L |
standing frame. Treatment decisions were made based upon current available literature and shared decision making between the patient. Outpatient physical therapy was prescribed to promote resistance upper body training to help promote bone growth in addition to his use of teriparatide. The patient was also followed by physical medicine and rehabilitation with which a standing frame was attempted but not achieved. After one year of treatment, care was transferred to another fracture liaison and bone health clinic. At the new site, the patient continued with teriparatide for an additional year, which was then discontinued due to its black box warning. There is a theoretical risk of osteosarcoma when medicating with teriparatide for more than 2 years. Vitamin D₃ supplementation was also continued, but at a greater dose, 3000 IU's once daily. While promoting bone formation with biologic measures, the mechanical goal of aligning the patient to a standing frame remained the same.

Outcome
Notable biomarkers from baseline to post one month of treatment revealed the following: procollagen-1 N-terminal peptide (P1NP) from 38 mcg/L to 70 mcg/L and C-terminal telopeptide (CTX) 209 pg/mL to 88 pg/mL, representing an increased bone formation and decreased bone resorption, respectively. The patient’s symptoms regarding immobility and fracture risk remained the same at that time. After two years of treatment, there was improvement in BMD represented at the left femoral neck [T-score -2.7] and left total hip [T-score -2.7] which both improved from baseline [T-score -3.4] (Table 1). Furthermore, the patient was capable of utilizing a standing frame and stood for the first time since before his injury 38 years prior.

Discussion
Our case revealed improvement in osteoporosis labs and physical symptoms during a two-year course of treatment. Once labs and bone density tests have leveled, we would expect them to be at a steady state barring overall health change. We believe the improvement seen in our patient’s BMD was supported by prescribing teriparatide, supplementing vitamin D, and utilizing a standing frame. During the time of management, we were not informed of the International Society for Clinical Densitometry (ISCD) guidelines and did not utilize them. This patient could have also been a good candidate to consider the latest technology VirtuoSt Stress Test due to the difficulty in patient positioning from his previous bone density imaging. VirtuoSt Stress Test is a Food Drug Administration (FDA) cleared virtual stress test that assesses BMD, bone strength, and fracture risk. Bone density does not fully assess bone strength and quality. Factors such as diet, smoking status, alcohol use, are also important associated factors to evaluate in a patient with osteoporosis. In this patient’s case, we focused on a weight training program aligned with a physical therapist to promote body strength which over time had weakened in addition to providing mechanical load to the skeleton.

Due to the black box warning on teriparatide, the patient’s medication was switched to denosumab, a monoclonal antibody against RANKL. The decision to transition to denosumab was extrapolated from the DATA-switch study. There has since been an update to teriparatide’s label, removing the black box warning. The decision to resume teriparatide after two years is determined by clinical decision making and risk-benefit considerations. Given the recent update regarding teriparatide, it is reasonable to evaluate the patient one year after denosumab to determine whether to consider a future return to an anabolic therapy such as teriparatide. It is important to accrue bone mass over time by structuring a sequence of pharmacologic therapy.

If our patient’s future progression becomes similar to previous studied cases, then we should expect a cessation in lab and bone density test improvement and minimal or no improvement of symptoms. For these reasons, it is important to illustrate the most recent findings of the pathophysiology, treatment, and management of SCI osteoporosis to reference optimal care and provide a basis for the derivation of future innovative therapies.

Although the pathophysiology of SCI osteoporosis has been distinctly outlined, the treatments’ efficacy remains limited. Current Treatments
An effective long-term treatment for SCI osteoporosis has not been established. Current treatment options include pharmacological and physical therapy interventions. Although there are no interventions which prevent or reverse SCI osteoporosis, bisphosphonates, a group of antiresorptive drugs, are the most common pharmacological treatment for bone loss prevention in these individuals. Unfortunately, bisphosphonates have mostly been shown to be effective within the first year post SCI. Studies have shown a 16.4% to 19.7% reduction in bone loss at the femoral neck and approximately 21% percent reduction in bone loss at the total hip when treating SCI osteoporosis with bisphosphonates within the first year. However, a single study revealed that a two year course of bisphosphonates following SCI reduces the risk of fracture for two years, but revealed no evidence of bone loss prevention following one year. Bisphosphonates aid in the prevention of acute bone loss following SCI, but have no effect on bone formation. Therefore, the effect of bisphosphonates is not substantial. This dilemma has encouraged further investigation for more desirable pharmacological treatments.

Teriparatide (TPTD), a recombinant human parathyroid hormone has recently gained attention as the optimal pharmacological treatment. TPTD is one of the few approved anabolic pharmacological treatments for osteoporosis and can be effective up until 24 months. It has also shown efficacy in treatment of SCI osteoporosis demonstrating a 4.8% to 5.5% increase in spinal BMD from baseline to 12 months. Furthermore, TPTD revealed a 3.1% to 14.4% increase in spinal BMD from baseline to 24 months. Along with these current drug therapies, denosumab, a monoclonal antibody against RANKL has been shown to increase BMD in individuals with SCI induced osteoporosis as well.

Table 1
Changes in Biomarkers from Baseline to Post One Month of Treatment

| Biomarker          | Baseline | Post One Month |
|--------------------|----------|---------------|
| P1NP               | 38 mcg/L | 70 mcg/L      |
| CTX                | 209 pg/mL| 88 pg/mL      |

Figure 1. Left knee x-ray (oblique, externally rotated). Diffuse bony demineralization reduces sensitivity of radiography for acute fracture. There is corticated deformity of the distal femur and proximal tibia from old, healed fractures. No clear evidence of a superimposed acute fracture.
As for physical therapy interventions, weight-bearing exercises, functional electrical stimulation (FES), and whole-body vibration (WBV) have been used to improve osteoporosis by increasing BMD.¹⁴ As we discussed earlier, sclerostin levels decrease with mechanical loading. Therefore, an increase of bone formation should be expected to follow weight-bearing exercises. Mechanical loading in SCI is a considerable challenge given the immobile state of the person. However, this challenge has been approached with FES exercises. FES treatment achieves mechanical loading by allowing electrodes to stimulate paralyzed muscles and facilitate muscle contraction. FES exercises have not been proven to provide long-term efficacy.

Whole body vibration (WBV) therapy also can achieve mechanical loading via mechanical vibration and is currently a potential treatment for bone formation in SCI. In fact, both human and animal studies have reported neurological function recovery with SCIs after WBV therapy.²⁴ The efficacy of WBV therapy on osteoporosis in SCI has not been thoroughly evaluated. However, one study was able to report an increase of percentage in BMD only at the knee after 12 months of WBV therapy.²⁵

Potential Treatments

Additional potential treatments for SCI induced osteoporosis include romosozumab, abaloparatide, activin receptor blockers, and cathepsin-K inhibitors. Romosozumab (ROMO) is a new anti-sclerostin drug that has revealed a significantly greater improvement in BMD and reduced fracture risk in comparison with teriparatide treatment in post-menopausal women with osteoporosis.²⁹ Although ROMO has not yet been approved for men due to serious cardiovascular side effect risks, it has shown promising results of BMD improvement in its phase III clinical trial.³⁰ There is a lack of research on the effects of ROMO administration on the bone metabolism of the SCI population.

Abaloparatide is a bone forming agent used to treat post-menopausal osteoporosis in women who have failed antiresorptive therapy or have a high risk of fracture. Abaloparatide usage reduces the risk of osteoporotic fractures and the prevalence of hypercalcemia in comparison with teriparatide. Furthermore, it is more cost effective than teriparatide.³¹ Again, there is a lack of research on the effects of abaloparatide administration on the bone metabolism of the SCI population. Not to mention, both romosozumab and abaloparatide have not yet been approved for males. Although romosozumab and abaloparatide have not proved their efficiency in SCI osteoporosis, they both remain potential pharmacological treatments.

Additional but less effective potential treatments currently being reviewed are type II activin receptor (ActRIIA) blockers and cathepsin-K inhibitors. Up to date, the efficacy of ActRIIA blockade has not been reviewed in people with SCI. Cathepsin-K is a protease involved in bone catabolism and research unveiled early bone loss prevention in post-menopausal women with cathepsin-K inhibitors.³² However, cathepsin-K inhibitors have been found to increase the risk of stroke which led to the termination of its development, specifically odanacatib.³³ Therefore, ActRIIA blockers and cathepsin-K inhibitors remain potential pharmacological treatments for SCI osteoporosis as well.

Management

As for management, serial dual-energy X-ray absorptiometry (DXA) scans are utilized concurrently with bone biomarker monitoring and correction.²⁵ Up to now, the identification of clinical improvement via DXA scans has been limited due to the absence of an established guideline for SCI osteoporosis. Fortunately, the ISCD recently developed a task force to perform a multi-study review of the DXA scan’s role during various aspects of SCI osteoporosis management. This review allowed the ISCD to create their official position statement on BMD testing in SCI. The official position statement reports the following verbatim:

“1. All adults with spinal cord injury resulting in permanent motor or sensory dysfunction should have a DXA scan of the total hip, proximal tibia, and distal femur as soon as medically stable.
2. In adults with SCI, total hip, distal femur and proximal tibia bone density should be used to diagnose osteoporosis, predict lower extremity fracture risk, and monitor response to therapy where normative data is available.
3. Serial DXA assessment of treatment effectiveness among individuals with SCI should include evaluation at the total hip, distal femur, and proximal tibia, following a minimum of 12 months of therapy at 1- to 2-year intervals. Segmental analysis of total hip, distal femur and proximal tibia sub-regions from a whole-body scan should not be used for monitoring treatment.
4. There is no established threshold BMD value below which weight-bearing activities are absolutely contraindicated. BMD and clinical risk factors should be used to assess fracture risk prior to engaging in weight-bearing activities.”

It is notable that the ISCD added the necessity of the person having sufficient turning radius for a manual or power wheelchair during the scan and that the chair must be equipped with a lift. Furthermore, focused areas containing artifacts should be recognized and should not be used for diagnosis, fracture risk assessment, or monitoring response to therapy. Some examples of artifacts include hardware, deformity, heterotopic ossification, contracture or movement (spasticity), or leg bag artifacts which prevent optimal position for scanning or limit the accuracy of the analysis.³⁴ The CTX is a marker of bone resorption (degradation) and the P1NP is a marker for bone formation.³⁵ The biomarkers are used as a tool to help identify the appropriate recommendations for treatment along with other factors in the patient’s history such as previous osteoporosis treatment plan, comorbid conditions, among other factors. In the literature, in treatment of naïve patients, an increase in P1NP was a predictor of BMD at 12 months.³⁶ There is no comparator to a median or expected ranges in this case but rather an improvement from baseline.

Conclusion

The findings in this case provide hope for bone health and strength in SCI patients as they continue to age with their disability. Newer anabolics, such as abaloparatide and romosozumab, have shown greater improvement than previous treatments in osteoporosis. We believe using optimal pharmacological agents, mechanical loading of the skeleton, and the ISCD guidelines will allow the best patient prognosis for SCI patients. The pathophysiology of spinal cord injury induced osteoporosis has been distinctly outlined. Our case exemplified progress that can be made with aggressive mechanical and biologic treatment. A basis for the derivation of future innovative therapies has been covered. Favorable treatments and management are referenced for best patient prognosis.

References

1. Bauman WA, Cardozo CP. Osteoporosis in Individuals with Spinal Cord Injury. PMRDR. 2014 Aug 27;7(2):188-201.
2. Dobbs NB, Buckwalter J, Saltzman C. Osteoporosis: The Increasing Role of the Orthopodist. Iowa Orthop J. 1999; 19:45-52.
3. Battaglino RA, Lazzari AA, Garshick E, Morse LR. Spinal Cord Injury-Induced Osteoporosis: Pathogenesis and Emerging Therapies. Curr Osteoporos Rep. 2012 Dec;10(4):278-85.
4. Tan CO. Spinal Cord Injury and Osteoporosis: Causes, Mechanisms, and Rehabilitation Strategies. Int J Med Rehabil. 2015;1(4):122.
5. National Spinal Cord Injury Statistical Center. Spinal Cord Injury Facts and Figures at a Glance. Available from https://www.mcri.uab.edu/Public/Facts%20and%20Figures%20at%20a%20Glance.pdf, last updated 2021; cited Jun 22, 2020.
6. National Spinal Cord Injury Statistical Center. Spinal Cord Injury Facts and Figures at a Glance. Available from https://www.mcri.uab.edu/Public/Facts%20and%20Figures%20at%20a%20Glance.pdf, last updated 2021; cited Jun 22, 2020.
Author Contributions

Conceptualization and Visualization: TS. Methodology, Supervision and Writing – Original Draft Preparation: AB. Writing – Review & Editing: TS and LW.

Cite as:

Bangura A, Shuler T, Wright L, Lake A. Spinal Cord Injury Induced Osteoporosis: Case Report and Current Literature. Int J Med Students. 2021 May-Jun;9(2):162-6.

This work is licensed under a Creative Commons Attribution 4.0 International License

ISSN 2076-6327

This journal is published by the University Library System, University of Pittsburgh as part of the Digital Publishing Program and is co-sponsored by the University of Pittsburgh Press.

Acknowledgments

None

Conflict of Interest Statement & Funding

The Authors have no funding, financial relationships or conflicts of interest to disclose.

The Authors have no funding, financial relationships or conflicts of interest to disclose.

Conflict of Interest Statement & Funding

None

StatPearls Publishing. Osteoporosis in Spinal Cord Injuries. Available from https://www.ncbi.nlm.nih.gov/books/NBK526109/ Last updated Dec 2 2020; cited Apr 23, 2020.

Wirth F, Schimpf G, Stein G, Wellmann K, Manthou M, Scholl C, et al. Whole-Body Vibration improves functional Recovery in Spinal Cord Injured Rats. J Neurotrauma. 2013 Mar 15;30(6):453-68.

Ness LL, Field-Fote EC. Whole-body vibration improves walking function in individuals with spinal cord injury: A pilot study. Curr Posture. 2009 Nov;3(3):236-40.

McClung MR. Romosozumab for the treatment of osteoporosis. Osteoporos Sarcopenia. 2018 Mar;7(1):1-5.

Lewiecki EM, Blicharski T, Goemaele S, Lippuner K, Meisner PD, Miller PD, et al. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. J Clin Endocrinol Metabol. 2018 Sept 11;103(6):3183-93.

Merlotti D, Falchetti A, Chiodoni L, Gennari L. Efficacy and safety of abaloparotide for the treatment of post-menopausal osteoporosis. Expert Opin Pharmacother. 2019 Mar;20(3):805-11.

McClung M, O'Donoghue M, Papapoulos S, Bone H, Langdahl B, Saag K. Odanacatib for the treatment of postmenopausal osteoporosis. results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. Lancer Diabetes Endocrinol. 2019 Dec 1;7(12):899-911.

Morse LR, Biering-Sørensen F, Carbone LD, Cervinka L, Cirnigliaro CM, Johnston TE, et al. Bone Mineral Density Testing in Spinal Cord Injury: 2019 ISCD Official Position. J Clinical Densitom. 2019 Oct;22(4):554-66.

Shetty S, Kapoor N, Bondu JD, Thomas N, Paul TV. Bone Turnover Markers: Emerging Tool in the Management of Osteoporosis. Indian J Endocrinol Metab. 2016 Nov-Dec; 20(6):684-85.

Tsujiimoto M, Chen P, Miyashita A, Sowa H, Kerez JH. PNP 32 as and Aid for Monitoring Patients Treated with Teriparatide. Bone. 2011 Apr 1; 48(4): 798-803.

Sclerostin Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength. J Bone Miner Res. 2008 Jun;13(6):860-9.

Morser LR, Sudhakar S, Danilkow V, Tun C, Lazzari A, Gagnon DR, et al. Association between sclerostin and bone density in chronic spinal cord injury. J Bone Miner Res. 2012 Feb;27(2):52-9.

Wu J, Ma L, Wu L, Jin Q. Wnt-β-catenin signaling pathway inhibition by sclerostin may protect against degradation in healthy but not osteoarthritic cartilage. Mol Med Rep. 2017 May;15(3):2429-33.

Wijayakusuma AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ. Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL Dependent Pathway. PLoS ONE. 2011 Oct;6(10):E25950.

Battaglino RA, Sudhakar S, Lazzari AA, Garshick E, Zafonte R, Morse LR. Circulating sclerostin is elevated in short-term and reduced in long-term SCI. Bone. 2012 Sept;51(3):600-5.

Morse LR, Sudhakar S, Lazzari AA, Tun C, Garshick E, Zafonte R, et al. Sclerostin: a candidate biomarker of SCI-induced osteoporosis. Osteoporos Int. 2013 Mar;24(2):961-8.

Lamarche J, Mailhot G. Vitamin D and spinal cord injury: should we care? Spinal Cord. 2016 Dec;54(12):1060–75.

Mechanic JL, Pomerantz F, Flanagan S, Stein A, Gordon WA, Ragnarsson KT. Parathyroid hormone suppression in spinal cord injury patients is associated with the degree of neurologic impairment and not the level of injury. Arch Phys Med Rehabil. 1997 Jul;78(7):692-6.

Drake M, Srimivasan B, Mödder U, Peterson J, McCready R, Riggs B, et al. Effects of Parathyroid Hormone Treatment on Circulating Sclerostin Levels in Postmenopausal Women. J Clin Endocrinol Metab. 2010 Nov;95(11):5066-62.

Yu EW, Kumbhari R, Siwia-Sackman E, Leder BZ. Acute Decline in Serum Sclerostin in Response to PTH Infusion in Healthy Men. J Clin Endocrinol Metab. 2011 Nov;96(11):E1848-51.

Savvidis C, Tournis S, Dede AD. Obesity and bone metabolism. Hormones. 2018 Apr;17(2):205-17.

Zhou Y, Rui L. Leptin signaling and leptin resistance. Front Med. 2013 Jun;7(2):207-22.

Jean JO, Steadward RD, Wheeler GD, Bell G, McCargar L, Harvard V. Intact Sympathetic Nervous System Is Required for Leptin Effects on Resting Metabolic Rate in People with Spinal Cord Injury. J Clin Endocrinol Metab. 2003 Jan;88(1):402-7.

Doherty AL, Battaglino RA, Donovan J, Gagnon D, Lazzari AA, Garshick E, et al. Adiponectin Is a Candidate Biomarker of Lower Extremity Bone Density in Men With Chronic Spinal Cord Injury. J Bone Miner Res. 2014 Jan;29(1):251-9.

Leder BZ, Tsai JH, Uhlein AV, Wallace PM, Lee H, Neer RM, et al. Denosumab and teriparatide transitions in post-menopausal osteoporosis (the DATA-switch study): extension of a randomized control trial. Lancet. 2015 Sep 19;386(9999):1147-55